These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32554613)

  • 1. FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion.
    Oldham RJ; Mockridge CI; James S; Duriez PJ; Chan HTC; Cox KL; Pitic VA; Glennie MJ; Cragg MS
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.
    Zhang M; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Brechbiel MW; Carrasquillo JA; Waldmann TA
    Cancer Res; 2004 Aug; 64(16):5825-9. PubMed ID: 15313926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.
    Xiu Y; Wong CP; Bouaziz JD; Hamaguchi Y; Wang Y; Pop SM; Tisch RM; Tedder TF
    J Immunol; 2008 Mar; 180(5):2863-75. PubMed ID: 18292508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model.
    Wen J; Wang L; Ren J; Kranz E; Chen S; Wu D; Kanazawa T; Chen I; Lu Y; Kamata M
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.
    Sharma SK; Chow A; Monette S; Vivier D; Pourat J; Edwards KJ; Dilling TR; Abdel-Atti D; Zeglis BM; Poirier JT; Lewis JS
    Cancer Res; 2018 Apr; 78(7):1820-1832. PubMed ID: 29363548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligation of Fc gamma RII (CD32) pivotally regulates survival of human eosinophils.
    Kim JT; Schimming AW; Kita H
    J Immunol; 1999 Apr; 162(7):4253-9. PubMed ID: 10201955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.
    Arriga R; Caratelli S; Lanzilli G; Ottaviani A; Cenciarelli C; Sconocchia T; Spagnoli GC; Iezzi G; Roselli M; Lauro D; Coppola A; Dotti G; Ferrone S; Sconocchia G
    Int J Cancer; 2020 May; 146(9):2531-2538. PubMed ID: 31396956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody-Drug Conjugate Via Fc-FcγR Interaction.
    Li F; Ulrich ML; Shih VF; Cochran JH; Hunter JH; Westendorf L; Neale J; Benjamin DR
    Mol Cancer Ther; 2019 Apr; 18(4):780-787. PubMed ID: 30824607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions.
    Sibéril S; de Romeuf C; Bihoreau N; Fernandez N; Meterreau JL; Regenman A; Nony E; Gaucher C; Glacet A; Jorieux S; Klein P; Hogarth MP; Fridman WH; Bourel D; Béliard R; Teillaud JL
    Clin Immunol; 2006; 118(2-3):170-9. PubMed ID: 16332457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases.
    Carreno BM; Garbow JR; Kolar GR; Jackson EN; Engelbach JA; Becker-Hapak M; Carayannopoulos LN; Piwnica-Worms D; Linette GP
    Clin Cancer Res; 2009 May; 15(10):3277-86. PubMed ID: 19447870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
    Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
    Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique monoclonal antibodies define expression of Fc gamma RI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells.
    Tan PS; Gavin AL; Barnes N; Sears DW; Vremec D; Shortman K; Amigorena S; Mottram PL; Hogarth PM
    J Immunol; 2003 Mar; 170(5):2549-56. PubMed ID: 12594281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of altered endogenous IgG on unspecific mAb clearance.
    Fuhrmann S; Kloft C; Huisinga W
    J Pharmacokinet Pharmacodyn; 2017 Aug; 44(4):351-374. PubMed ID: 28439684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
    Kashyap MK; Amaya-Chanaga CI; Kumar D; Simmons B; Huser N; Gu Y; Hallin M; Lindquist K; Yafawi R; Choi MY; Amine AA; Rassenti LZ; Zhang C; Liu SH; Smeal T; Fantin VR; Kipps TJ; Pernasetti F; Castro JE
    J Hematol Oncol; 2017 May; 10(1):112. PubMed ID: 28526063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD16
    Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
    Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.
    Pollastrini J; Dillon TM; Bondarenko P; Chou RY
    Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
    Bruckheimer EM; Fazenbaker CA; Gallagher S; Mulgrew K; Fuhrmann S; Coffman KT; Walsh W; Ready S; Cook K; Damschroder M; Kinch M; Kiener PA; Woods R; Gao C; Dall'Acqua W; Wu H; Coats S
    Neoplasia; 2009 Jun; 11(6):509-17, 2 p following 517. PubMed ID: 19484140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains.
    Agliano A; Martin-Padura I; Mancuso P; Marighetti P; Rabascio C; Pruneri G; Shultz LD; Bertolini F
    Int J Cancer; 2008 Nov; 123(9):2222-7. PubMed ID: 18688847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.